Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week.
Browsing: Demyelinating disease
Results from the Phase III EXPAND study of siponimod in secondary progressive multiple sclerosis have been announced, revealing that the drug reduced the risk of disability progression.
Results from an international trial have demonstrated that hematopoietic stem cell transplantation is an effective and safe treatment for patients with relapsing multiple sclerosis.
Editor’s summary considering the effectiveness and tolerability of octagam in patients with chronic inflammatory demyelinating polyneuropathy.
New research reveals that individuals exposed to more of the sun’s rays, particularly in their youth, are less likely to go on to develop multiple sclerosis.
The US FDA has issued a refusal-to-file against a key multiple sclerosis drug – ozanimod – due to insufficient data for one of the most important pipeline assets of Celgene.
Sarah Isabel Sheikh talks to Neurodegenerative Disease Management about her research into the development of neuroregenerative-based therapies for multiple sclerosis.
In this interview from Neurodegenerative Disease Management, hear from Shibeshih Belachew (Roche) on the future of multiple sclerosis trials and therapeutics.
Researchers have discovered that a simple blood test to detect a nerve protein, neurofilament light chain, may be an efficient way to monitor symptoms in patients with relapsing-remitting MS.
Although exercise training has been advocated as a nonpharmacological treatment for multiple sclerosis-related fatigue, no consensus exists regarding its effectiveness.